StockData

TFA Therapeutics, Inc. (RAJAF) stock

RAJAFOTCMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on May 15, 2026Score 7/30
$9.18+0.00 (0.00%)

Close on Oct 16, 2026Market cap –P/E –Yield –

TFA Therapeutics gross margin

Gross margin is gross profit as a percentage of revenue.

TFA Therapeutics's gross margin for the twelve months ending Dec 31, 2023 was 86.8%. For fiscal 2025 it was 61.1%, against 72.3% the year before. The highest annual figure on record is 86.8% in fiscal 2023.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202561.1%−11.2
FY2024Dec 31, 202472.3%−14.5
FY2023Dec 31, 202386.8%+12.6
FY2022Dec 31, 202274.2%+94.3
FY2021Dec 31, 2021-20.0%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q4 FY2023Dec 31, 202390.2%–

More TFA Therapeutics figures

See a number that looks wrong?